OraSure Technologies, Inc. (NASDAQ:OSUR) Shares Sold by Russell Investments Group Ltd.

Russell Investments Group Ltd. trimmed its position in shares of OraSure Technologies, Inc. (NASDAQ:OSUR - Free Report) by 24.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 320,419 shares of the medical instruments supplier's stock after selling 102,134 shares during the period. Russell Investments Group Ltd. owned approximately 0.43% of OraSure Technologies worth $1,157,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in OSUR. Raymond James Financial Inc. bought a new position in OraSure Technologies during the 4th quarter valued at $37,000. AXQ Capital LP acquired a new position in OraSure Technologies in the fourth quarter worth about $51,000. RPO LLC bought a new stake in OraSure Technologies in the fourth quarter valued at about $56,000. US Bancorp DE raised its position in shares of OraSure Technologies by 310.4% during the 4th quarter. US Bancorp DE now owns 19,433 shares of the medical instruments supplier's stock valued at $70,000 after acquiring an additional 14,698 shares in the last quarter. Finally, Aigen Investment Management LP bought a new position in OraSure Technologies during the fourth quarter worth $76,000. 93.50% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at OraSure Technologies

In other OraSure Technologies news, CEO Manner Carrie Eglinton purchased 78,625 shares of OraSure Technologies stock in a transaction on Thursday, February 27th. The stock was bought at an average price of $3.15 per share, for a total transaction of $247,668.75. Following the transaction, the chief executive officer now owns 1,259,664 shares of the company's stock, valued at $3,967,941.60. The trade was a 6.66 % increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director John P. Kenny purchased 47,659 shares of the stock in a transaction dated Thursday, February 27th. The shares were acquired at an average cost of $3.17 per share, for a total transaction of $151,079.03. Following the completion of the acquisition, the director now directly owns 70,915 shares of the company's stock, valued at approximately $224,800.55. This trade represents a 204.93 % increase in their position. The disclosure for this purchase can be found here. Over the last 90 days, insiders have bought 190,284 shares of company stock worth $600,348. 3.90% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Separately, StockNews.com downgraded shares of OraSure Technologies from a "buy" rating to a "hold" rating in a research report on Tuesday, March 4th.

OraSure Technologies Price Performance

Shares of OSUR stock traded down $0.06 during trading hours on Friday, reaching $2.98. The stock had a trading volume of 66,205 shares, compared to its average volume of 871,648. The firm has a market capitalization of $222.53 million, a PE ratio of 19.83 and a beta of 0.76. The firm has a 50-day simple moving average of $3.33 and a 200-day simple moving average of $3.71. OraSure Technologies, Inc. has a twelve month low of $2.69 and a twelve month high of $5.59.

OraSure Technologies announced that its board has approved a share repurchase program on Monday, March 24th that authorizes the company to buyback $40.00 million in outstanding shares. This buyback authorization authorizes the medical instruments supplier to repurchase up to 15.6% of its stock through open market purchases. Stock buyback programs are often a sign that the company's management believes its shares are undervalued.

About OraSure Technologies

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company's products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.